Kidney Therapy Articles & Analysis

To learn how Xeltis’ restorative hemodialysis access graft, aXess, may be opening new horizons for patients with kidney failure, tune in the Visionary Endovascular and Vascular Education (VERVE) Symposium in Sidney, up to 4 December. In his talk on Saturday 4 December (10am AET), Professor Frans L. Moll, University Medical Center, Utrecht (NL) will explain how the Xeltis synthetic device ...

By XELTIS BV

Quanta Dialysis Technologies Inc (“Quanta or “The Company”), a medical technology company committed to making kidney care more accessible with its SC+ hemodialysis system, announced today that CEO John E. Milad will leave the company effective July 15, 2022. The company has begun the search for a new CEO. Upon Milad’s departure and until the appointment of a new CEO, ...

By QUANTA Dialysis Technologies

Xeltis has initiated the clinical trial for aXess, the first-ever restorative synthetic haemodialysis access graft. Several patients with kidney failure or advanced kidney disease requiring dialysis have already been successfully implanted as part of a European first-in-human trial to date. The aXess grafts enable early puncturing, or initiation of the dialysis, shortly after implanting. ...

By XELTIS BV

QUANTA Dialysis Technologies Ltd (“QUANTA” or the “Company”), a medical technology company committed to making kidney care more accessible with its SC+ haemodialysis system, has released a new report that suggests people with kidney failure who wish to do home dialysis face unequal access across the UK. The Bridging the Gap report finds that failure to offer such treatment ...

By QUANTA Dialysis Technologies

Notitia Biotechnologies Company has developed a ground-breaking live biotherapeutic product (LBP) for patients with early-stage and end-stage diabetic kidney disease (DKD) patients. The drug, NBT-BM306, combines the purified Foundation Guild bacteria and the tailored microbiome nutrition to support their growth in one convenient format. Notitia is preparing the Investigational New Drug (IND) ...

By Notitia Biotechnologies

Healionics Corporation, a private medical device company, announced today the completion of a $4.5M convertible note financing round. The financing supports the first human study, currently underway, of the company's innovative STARgraft vascular graft. In preclinical studies, STARgraft demonstrated improved ability to maintain blood flow compared to on-market vascular grafts, thereby offering ...

By Healionics

Cara Therapeutics, Inc. (Nasdaq: CARA), an early commercial-stage biopharmaceutical company leading a new treatment paradigm to improve the lives of patients suffering from pruritus, today announced biomarker data from the KALM-1 and KALM-2 clinical trials evaluating KORSUVA™ (difelikefalin) injection for the treatment of chronic kidney disease-associated pruritus in patients undergoing ...

By Cara Therapeutics.

Prof. M.S Sandhu from PGIMER Chandigarh #Radiology Department – India. recently gave an interview in which he illustrated the peculiarities of automatic CO2 angiography. In this interview, Prof. Sandhu remarked the Angiodroid technology. Here is a brief excerpt: “A recently developed injector with a very novel method to map these vessels is to use carbon dioxide as a ...

By Angiodroid Spa

OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnemo: OSE) today announced that the first participant has been dosed in a Phase 1 Study of VEL-101/FR104 [NCT05238493], a study sponsored and conducted by its partner in transplantation, Veloxis Pharmaceuticals, Inc., an Asahi Kasei company. VEL-101/FR104 is a novel investigational maintenance immunosuppressive agent being developed for prevention ...

By OSE Immunotherapeutics

Alkahest Inc., a clinical stage biotechnology company focused on discovering and developing transformative therapies to treat age-related diseases, today announced the initiation of a clinical study to explore the use of an extracorporeal medical device to remove excess Beta-2 microglobulin (B2M) from circulation for the treatment of cognitive impairment in patients undergoing hemodialysis for ...

By Alkahest, Inc.

Apollo Medical Holdings, Inc. ("ApolloMed," and together with its subsidiaries and affiliated entities, the "Company") (NASDAQ: AMEH), a leading physician-centric, technology-powered healthcare company focused on enabling providers in the successful delivery of value-based care, today announced that ApolloMed received certification from the National Committee for Quality Assurance ("NCQA") for ...

By Apollo Medical Holdings, Inc.

Healionics Corporation, a Seattle-based medical device company, was awarded a $1.5M Phase II Small Business Innovation Research (SBIR) grant from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) of the National Institutes of Health (NIH) to develop new vascular grafts for dialysis use that overcome the major problem of clotting failure. Andrew Marshall, Ph.D., ...

By Healionics

Healionics Corporation, a Seattle-based medical device company, today announced the appointment of Mike Connolly as Chief Executive Officer. Connolly brings 25 years of leadership in the medical device industry including extensive experience in both operating and venture investing roles. “We are fortunate to add a leader of Mike’s caliber,” said Andrew Marshall, Director and ...

By Healionics

On May 31, 2021, Mr. Dominic Barton, Canadian Ambassador to China, accompanied by Consul General Jeff David and trade commissioners from the Canadian Consulate General in Chongqing, visited SWS ...

By SWS Hemodialysis Care Co., Ltd.

Procedure removes risk of kidney injury or complications in patients with advanced kidney disease or allergy to contrast dye On Sept. 30, CentraCare completed the world’s first contrast-free WATCHMAN implant using 4D holographic therapy guidance, developed by EchoPixel, as the alternative imaging modality. Rather than relying on contrast dye and X-ray based imaging to help guide the ...

By EchoPixel, Inc.

EchoPixel has once again contributed to a pioneering procedure at CentraCare – St. Cloud Hospital with the first team to remove a heart tumor without invasive open heart surgery using the novel AlphaVac catheter. Previously CentraCare had been the first to use EchoPixel’s 4D hologram technology to conduct the WATCHMAN implant, which is a one-time, minimally invasive procedure ...

By EchoPixel, Inc.

A new study shows significant benefits of the Ellipsys Vascular Access System in easily and safely creating durable vascular access for end-stage renal disease (ESRD) patients who require hemodialysis. It also offers a standardized process for using the minimally invasive technology that other physicians can follow to reproduce the results, which “will make it easier for more practitioners ...

By Avenu Medical, Inc.

Healionics Corporation, a Seattle-based medical device company, has received notice from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) of a $1.7M Fast-Track Small Business Innovation Research (SBIR) grant in support of regulatory approval and a clinical study of STARgraftTM, its innovative synthetic vascular graft. Andrew Marshall, Healionics’ Chief Technology ...

By Healionics

Committee for Medicinal Products for Human Use (CHMP) recommends approval of Kapruvia® (difelikefalin) as first therapy in Europe for the treatment of chronic kidney disease associated-pruritus (CKD-aP) in hemodialysis patients European Commission decision for EU Marketing Authorization is expected in Q2 2022 Kapruvia® is approved in the U.S. under the trade name KORSUVA™ ...

By Cara Therapeutics.

Cara Therapeutics, Inc. (Nasdaq: CARA), an early commercial-stage biopharmaceutical company leading a new treatment paradigm to improve the lives of patients suffering from pruritus, today announced that its licensing partner Maruishi Pharmaceutical Co., Ltd., and its sublicensee Kissei Pharmaceutical Co., Ltd., confirmed the primary endpoint was achieved in a Japanese Phase 3 clinical study ...

By Cara Therapeutics.